more_reports

AI Chronic Care Platform Adds Fifth Fortune 50 Client, Lifts Margin to 62%

  ()
DarioHealth reported Q2 revenue of $5.2 million with gross margin rising to 62 percent and contracted ARR reaching $13.1 million after signing a fifth Fortune 50 client and expanding provider-backed care.
Tags: Life Sciences Tools & Diagnostics

DarioHealth Reports Q2 Revenue, with 62% Gross Margin as AI Platform Expands

  ()
DarioHealth Corp. (DRIO:NASDAQ) reported US$5.2 million in Q2 revenue, a 62% gross margin and US$13.1 million in contracted and late-stage ARR.
Tags: Life Sciences Tools & Diagnostics

GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review

  ()
GRAIL Inc. prepares for its Sept. 23 FDA advisory committee meeting on the Galleri MCED test PMA, backed by large clinical studies and growing commercial revenue in the expanding multi-cancer early detection market.
Tags: Life Sciences Tools & Diagnostics

Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review

  ()
GRAIL Inc. (GRAL:NASDAQ) announces that an FDA committee will meet in September to evaluate the Premarket Approval (PMA) application for the Galleri multi-cancer early detection (MCED) blood test. Read why one financial expert thinks it will gain approval.
Tags: Life Sciences Tools & Diagnostics

Digital Health Provider Launches Women's Health and Sleep Solutions

  ()
DarioHealth expands its cardiometabolic platform with Dario Women and Dario Sleep programs. Revenue contribution expected late 2026 amid rising demand for multi-condition digital care solutions.
Tags: Healthcare Services

AI Health Platform Expands Into Women's Health and Sleep With New Revenue Expected in Q4

  ()
DarioHealth Corp. (DRIO:NASDAQ) launched Dario Women and Dario Sleep, expanding its provider-backed cardiometabolic platform with programs expected to begin contributing recurring revenue in the fourth quarter.
Tags: Healthcare Services

Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial

  ()
Evommune begins Phase 2b testing of oral MRGPRX2 antagonist EVO756 for migraine prevention. The placebo-controlled study targets 330 patients with doses up to 100 mg and reports data in 2027.
Tags: Biotechnology / Pharmaceuticals

Myelofibrosis Combo Advances as Karyopharm Preps August sNDA

  ()
Karyopharm Therapeutics plans an sNDA filing for selinexor plus ruxolitinib in myelofibrosis. SVR35 endpoint and Phase 3 SENTRY data support the accelerated approval path.
Tags: Biotechnology / Pharmaceuticals

Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market

  ()
Sarepta Therapeutics contends with an FDA clinical hold on Elevidys following safety signals, while the Duchenne muscular dystrophy market projects strong growth through 2030.
Tags: Biotechnology / Pharmaceuticals

NY Telehealth Extension Advances Rocket Doctor AI Platform

  ()
Rocket Doctor AI extends its New York telehealth engagement through 2029, combining grants and Medicaid to serve underserved patients while scaling its AI platform amid strong digital health market growth.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

PFAS Treatment System Processes 2 Million Gallons at New Jersey Site

  ()
BioLargo's AEC technology has treated over 2 million gallons of PFAS-contaminated water in New Jersey while meeting regulatory standards. Learn how the system reduces waste and costs compared with traditional methods.
Tags: CleantechTechnologySpecial Situations

This AI Healthcare Platform Is Taking Its New York Expansion Through 2029

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) extended its EngageWell partnership after an initial virtual-care pilot connected more than 400 underserved New Yorkers with physician-led care.
Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsArtificial IntelligenceTechnology

Cleantech Company Delivers PFAS Removal Breakthrough in New Jersey

  ()
BioLargo Inc. (BLGO:OTCQX) announces the processing of more than 2 million gallons of PFAS-contaminated water using its patented Aqueous Electrostatic Concentrator (AEC) technology. Find out why one technical analyst likes BLGO's business model.
Tags: CleantechTechnologySpecial Situations

Evommune Doses First Patient in Migraine Trial

  ()
Evommune Inc. (EVMN:NYSE) dosed its first patient in a Phase 2b trial of EVO756, an oral migraine prevention drug targeting the MRGPRX2 receptor.
Tags: Biotechnology / Pharmaceuticals

Karyopharm Pursues Myelofibrosis FDA Milestone

  ()
Karyopharm Therapeutics Inc. (KPTI:NASDAQ) prepares an FDA filing for selinexor plus ruxolitinib after Phase 3 results, targeting the first approved combination therapy for myelofibrosis.
Tags: Biotechnology / Pharmaceuticals

Sarepta Grants New CEO 2.2M Stock Options Amid "Sell" Rating

  ()
Sarepta Therapeutics Inc. (SRPT:NASDAQ) granted CEO Michael Severino options for 2,224,342 shares and 756,104 RSUs as an inducement award tied to his hiring.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Digital Health Firm Launches Integrated GLP-1 Program

  ()
DarioHealth integrates its digital platform with licensed providers to offer end-to-end GLP-1 support. See how the new program targets employers and health plans in a growing market.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

New GLP-1 Platform Combines Doctor Prescriptions, AI Coaching and Chronic Care

  ()
DarioHealth Corp. (NASDAQ: DRIO) introduced its Integrated GLP-1 Program, bringing licensed provider evaluations, FDA-approved GLP-1 prescribing where clinically appropriate and ongoing care into one experience.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Dyadic C1 Platform Delivers Ebola Antigens in 15 Days

  ()
Dyadic International produced two Bundibugyo ebolavirus antigens in about 15 days using its C1 platform and delivered them for preclinical testing amid an active outbreak in Africa.
Tags: Biotechnology / Pharmaceuticals

Biotech Produces Ebola Proteins in Just 15 Days as African Outbreak Intensifies

  ()
Dyadic International Inc. (NASDAQ: DYAI) has rapidly developed and produced recombinant protein antigens targeting Bundibugyo ebolavirus, progressing from receipt of the plasmids to purified proteins in approximately 15 days. As the Ebola outbreak in Africa continues, this achievement highlights the speed and potential of Dyadics C1 protein-production platform. Read why one technical analyst believes DYAIs' stock could be positioned for a bullish move.
Tags: Biotechnology / Pharmaceuticals

Blood in the Streets: Why I'm Buying Gold Miners, a Peru Tailings Giant, and Two Biotech 10-Baggers This Summer

Contributed Opinion
  ()
Newsletter writer Chen Lin shares his view on the current state of the market and shares some stocks on his list.
Tags: GoldBiotechnology / PharmaceuticalsTechnologyCopperSilver